Business Description
Jasper Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US4718712023
Share Class Description:
JSPR: Ordinary SharesTotal Employee Number:
22Description
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 18.68 | |||||
Equity-to-Asset | 0.16 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 32 | |||||
3-Year EPS without NRI Growth Rate | 31.8 | |||||
3-Year FCF Growth Rate | 31.9 | |||||
3-Year Book Growth Rate | -75 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 35.09 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.33 | |||||
9-Day RSI | 38.17 | |||||
14-Day RSI | 35.65 | |||||
3-1 Month Momentum % | -3.75 | |||||
6-1 Month Momentum % | -53.92 | |||||
12-1 Month Momentum % | -84.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.26 | |||||
Quick Ratio | 2.26 | |||||
Cash Ratio | 1.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -94.5 | |||||
Shareholder Yield % | 6.26 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -328.36 | |||||
ROA % | -127.54 | |||||
ROIC % | -1255.34 | |||||
3-Year ROIIC % | 628.84 | |||||
ROC (Joel Greenblatt) % | -3762.65 | |||||
ROCE % | -256.39 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.68 | |||||
Price-to-Tangible-Book | 3.68 | |||||
EV-to-EBIT | 0.01 | |||||
EV-to-EBITDA | 0.01 | |||||
EV-to-Forward-EBITDA | -0.07 | |||||
EV-to-FCF | 0.01 | |||||
| Price-to-Net-Current-Asset-Value | 4.91 | |||||
Earnings Yield (Greenblatt) % | No Debt | |||||
FCF Yield % | -556.91 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:JSPR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jasper Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.23 | ||
| Beta | 2.3475 | ||
| 3-Year Sharpe Ratio | -0.5 | ||
| 3-Year Sortino Ratio | -0.69 | ||
| Volatility % | 64.3 | ||
| 14-Day RSI | 35.65 | ||
| 14-Day ATR ($) | 0.081284 | ||
| 20-Day SMA ($) | 0.466795 | ||
| 12-1 Month Momentum % | -84.81 | ||
| 52-Week Range ($) | 0.3151 - 7.19 | ||
| Shares Outstanding (Mil) | 28.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jasper Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jasper Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 132 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 43 days | ||
| General meeting for 2026 | 2026-07-31 10:00 | In 31 days | ||
| First quarter earnings results for 2026 | 2026-05-14 | 0.92 (-3.15%) | ||
| Annual report for 2025 | 2026-03-30 | 1.05 (-6.25%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 1.05 (-6.25%) | ||
| 46(th) Annual TD Cowen Healthcare Conference | 2026-03-02 15:50 | 1.38 (+2.22%) | ||
| Chronic Urticaria Data Update Webinar | 2026-01-08 08:00 | 2.05 (+7.89%) | ||
| 8th Annual Evercore Healthcare Conference | 2025-12-03 15:00 | 1.58 (-26.17%) | ||
| Investor Webinar | 2025-12-02 08:00 | 1.72 (-5.49%) |
Show
Entries
Jasper Therapeutics Inc Frequently Asked Questions
What is Jasper Therapeutics Inc(JSPR)'s stock price today?
The current price of JSPR is $0.44. The 52 week high of JSPR is $7.19 and 52 week low is $0.32.
When is next earnings date of Jasper Therapeutics Inc(JSPR)?
The next earnings date of Jasper Therapeutics Inc(JSPR) is 2026-08-13 Est..
Does Jasper Therapeutics Inc(JSPR) pay dividends? If so, how much?
Jasper Therapeutics Inc(JSPR) does not pay dividend.
Guru Commentaries on NAS:JSPR
No articles.
Press Release
Articles on Jasper Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers